Assay News and Research

RSS

Abbott submits ARCHITECT 25-OH Vitamin D assay application to FDA for clearance

According to a recent report from the U.S. Centers for Disease Control and Prevention, a third of Americans have vitamin D levels that are either inadequate or deficient. While many people know that vitamin D is necessary to help the body absorb calcium, which helps create strong bones and muscles, many don't know that insufficient levels of this important vitamin may lead to other health problems.

16 Apr 2011

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it entered into a clinical validation agreement with University North Carolina Kidney Center, Chapel Hill, to evaluate SQI's new multiplexed, automated approach for biomarker detection in vasculitis.

15 Apr 2011

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

A Taiwanese research team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University has partnered with a research group led by Dr. Dennis Whitefield from National Research Council of Canada to develop innovative cancer diagnostic and treatment technologies.

15 Apr 2011

Enigma initiates ML system trial in patients with influenza

Enigma Diagnostics announced today that it has commenced clinical trials for its intended point of care Enigma ML Influenza A/B detection assay. Enigma will submit its application to the U.S. Food and Drug Administration for approval of the assay in 2012.

11 Apr 2011

Cellix expands European distribution network with Tebu-bio

Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.

11 Apr 2011

Cepheid receives FDA clearance for new assay to detect C. difficile infection

The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C. difficile/Epi assay that is designed to rapidly detect the toxin B gene associated with Clostridium difficile infection, a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death in severe cases.

11 Apr 2011

Gene expression changes in prostate tissue surrounding cancer lesions may allow prostate cancer diagnosis

Researchers have found that gene expression changes in prostate tissue surrounding cancer lesions may allow diagnosis of prostate cancer even if no cancer cells are present in biopsy tissue, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

8 Apr 2011

ChanTest to provide new system for LGIC and VGIC screening

Beginning next month, ChanTest Corporation will offer the highest throughput electrophysiology platform on the market validated for both voltage-gated and rapidly desensitizing ligand-gated ion channels.

7 Apr 2011

Cernostics, Definiens enter partnership to develop unique cancer assay

Definiens, the number one Health Image Intelligence company, and Cernostics, a life sciences firm specializing in advanced cancer diagnostics, today announced a partnership to develop a unique multiplexed assay tool for the diagnosis of cancer.

7 Apr 2011

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's to discuss FDA directives on immunogenicity introduced in 2008.

6 Apr 2011

Novel biomarker test accurately detects proteins secreted from asbestos-related tumors

Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Axxora.com to distribute TGR's new ELISAONE technology assay reagents in the US and South America

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Axxora.com of San Diego, CA, US, a leading online global market place resource for innovative and high quality Life Science research reagents.

4 Apr 2011

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.

From Quest Diagnostics 4 Apr 2011

Techne's R&D Systems acquires Boston Biochem assets

Techne Corporation announced today that as of April 1, 2011, its R&D Systems subsidiary has acquired the assets of Boston Biochem, Inc., a leading developer and manufacturer of innovative ubiquitin-related research products.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million in cash, providing QIAGEN with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.

From QIAGEN Manchester Limited 4 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Scientists develop new experimental diagnostic test to distinguish infection from disease

A potential new experimental diagnostic test able to quickly distinguish individuals with active tuberculosis from those with latent TB infection has been developed. If the preliminary results of the study will be confirmed in a larger population sample, the new diagnostic system could allow more effective strategies to control the spread of the re-emerging pathology.

1 Apr 2011

New lifesaving technology can combat cancer

Imagine the benefits if there was technology that pinpointed exactly which chemotherapy drugs work best in fighting each individual's type of cancer. No more guessing. No more trial and error. The good news is that such lifesaving technology is on its way to becoming reality.

1 Apr 2011

PGXL to utilize AutoGenomics' automated INFINITI analyzer for personalized medicine applications

PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.

1 Apr 2011

Assay News and Research

Abbott submits ARCHITECT 25-OH Vitamin D assay application to FDA for clearance

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

Enigma initiates ML system trial in patients with influenza

Cellix expands European distribution network with Tebu-bio

Cepheid receives FDA clearance for new assay to detect C. difficile infection

Gene expression changes in prostate tissue surrounding cancer lesions may allow prostate cancer diagnosis

ChanTest to provide new system for LGIC and VGIC screening

Cernostics, Definiens enter partnership to develop unique cancer assay

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

Novel biomarker test accurately detects proteins secreted from asbestos-related tumors

Axxora.com to distribute TGR's new ELISAONE technology assay reagents in the US and South America

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Techne's R&D Systems acquires Boston Biochem assets

Life Technologies launches new TaqMan Mutation Detection Assays

QIAGEN to acquire Cellestis

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Scientists develop new experimental diagnostic test to distinguish infection from disease

New lifesaving technology can combat cancer

PGXL to utilize AutoGenomics' automated INFINITI analyzer for personalized medicine applications

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News